What is RA Phase 2-3 Study Tasocitinib (CP-690,550)?
CATEGORY:
NCT00413699 is a long-term, open-label follow-up study of tasocitinib (CP-690,550) for treatment of rheumatoid arthritis. Other study IDs include: A3921024.
Save up to 80% off your prescriptions!
How do members experience RA Phase 2-3 Study Tasocitinib (CP-690,550)?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Rheumatoid arthritis | 2 | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 0 | |
| Mild | 0 | |
| None | 1 |
Learn more about our community’s experience with RA Phase 2-3 Study Tasocitinib (CP-690,550)
What are people saying about RA Phase 2-3 Study Tasocitinib (CP-690,550)?
2
2
members have reported taking RA Phase 2-3 Study Tasocitinib (CP-690,550)
Join the conversation and connect with people who have taken RA Phase 2-3 Study Tasocitinib (CP-690,550)
Last updated: